Wall Street's Finest, the inside hotline, for the hottest stocks picks you idiots could never find!

Saturday, April 28, 2018

The much anticipated

Children hanging on to the back of a moving london bus branded 'reckless'

News

Children hanging on to the back of a moving London bus branded 'reckless'

These three youngsters hanging on the back of a bus have been slammed by police (Picture: Islington MPS) Three reckless youngsters have been caught on camera hanging off the back of a moving bus in London.
Islington Police released a photo, taken near Archway Tube station.

Three British people die in 'helicopter accident' at Grand Canyon Steve Burton, TfL’s Director of Compliance, Policing and On Streets Services, told the Evening Standard those involved put the safety of themselves and the public at danger.
He said: ‘This behaviour is extremely reckless and will not be tolerated.
‘The actions of these individuals not only pose a risk to their personal safety, but also the safety of the drivers and passengers.’
This was snapped by a member of the public and sent in to us. Three children hanging on to the back of a moving bus. Obviously very dangerous, if you see this kind of activity yourself please call 999. @TfL pic.twitter.com/NiM5gE8geP
— Islington MPS (@MPSIslington) February 10, 2018
The Islington police officers’ post read: ‘This was snapped by a member of the public and sent in to us. Three children hanging on to the back of a moving bus.
‘Obviously very dangerous, if you see this kind of activity yourself please call 999.’
More: UK

Scout leader dismissed for comparing Muslim colleague wearing a niqab to Darth Vader

Manhunt for sex attacker who tried to rape girl in broad daylight

Rescuers in a raft save cat that fell off bridge and into river
The police have launched an investigation, adding that if anyone sees others doing the same thing, they should call 999.
Metro.co.uk has approached The Metropolitan Police for a statement.
MORE: Teachers get off lighter than pupils for cheating in exams
MORE: Council asks rich residents to pay more tax to help poor

Facebook Twitter Google+ LinkedIn StumbleUpon Pinterest

News from our partners

Close Modal

Cookies help us deliver our services. By using our services, you agree to our use of cookies.Learn more OK

Monday, April 9, 2018

J&J loses trial over claims linking cancer to asbestos in talc in New Brunswick , Nj. JNJ also has mega lawsuits on 2 bipolar medications called debakote, which causes fetal alcohol syndrome effects in pregnant and the drug churns your liver worse than drinking alcohol. The other mega lawsuit against JNJ is on drug risperdal which over time can make men's tits grow , and 40 percent of users treated have a hypoallergenic effect which causes self induced seizures in the victim. JNJ IS A CAN OF WORMS IF YOU ASK ME!

Novartis expands with acquisition, while
J&J loses trial over claims linking cancer to asbestos in talc
April 9, 2018
By Charles Graham aka Vanilla spilla

(Reuters) - Johnson & Johnson (JNJ.N) suffered its first trial loss in a lawsuit claiming its talc-based products including Johnson's Baby Powder contain cancer-causing asbestos, with a New Jersey jury on Thursday ordering J&J and another company to pay $37 million in damages.

The verdict of liability in Middlesex County Superior Court in New Brunswick came as J&J fights thousands of cases claiming its talc products can also cause ovarian cancer. The jury found J&J and another company liable after more than two months of trial.

The lawsuit was brought by New Jersey resident Stephen Lanzo, who said he developed mesothelioma after inhaling dust that was generated through his regular use of J&J talc powder products since his birth in 1972.

Mesothelioma is a deadly form of cancer closely associated with exposure to asbestos. It affects the delicate tissue that lines body cavities, most often around the lungs, but also in the abdomen and elsewhere.

The jury awarded Lanzo $30 million and his wife $7 million in compensatory damages. It found J&J was responsible for 70 percent of the damages and said a unit of France-based Imerys SA (IMTP.PA), its talc supplier, was responsible for 30 percent.

The jury will return on Tuesday for further proceedings to determine whether to award punitive damages, according to an online broadcast of the trial by Courtroom View Network.

J&J denied the allegations and says Johnson's Baby Powder does not contain asbestos or cause cancer.

J&J in a statement said it was disappointed but would withhold further comment until the trial's completion. Gwen Myers, an Imerys spokeswoman, said Imerys plans to appeal and is confident talc did not cause Lanzo's cancer.

The Lanzos did not respond to requests for comment.

J&J, based in New Brunswick, New Jersey, faces talc-related lawsuits by 6,610 plaintiffs nationally, largely based on claims it failed to warn women about the risk of developing ovarian cancer by using its products for feminine hygiene.

Story Continues
Start the conversation

What to Read Next
2019 Chevy Camaro reveals radical new face
Autoblog
This Stock Could Be Like Buying Amazon For $3.19
The Motley Fool
Sponsored

Senator's son to seek new civil trial against Joe Arpaio
Associated Press
MARKETS: Here's how China could really hurt the US—and it's not currency devaluation
Yahoo Finance Video
Futures point higher, Trump calls current China tariff deal 'stupid'
Yahoo Finance
Latest Dental Implant Prices May Leave You Smiling
Nation
Sponsored

Facebook to send Cambridge Analytica data-use notices Monday
Associated Press
WSJ: SpaceX not to blame for 'Zuma' spy satellite disaster
Engadget
As U.S. and China trade tariff barbs, others scoop up U.S. soybeans
Reuters
Check Debt Relief Eligibility – Do You Qualify For Relief?
National Debt Relief
Sponsored

CenturyLink’s latest way to avoid customer lawsuits is the most creative yet
BGR News
MARKETS: Tech stocks are lifting risk markets today
Yahoo Finance Video
Morning Brief: Facebook to begin notifying users about their data
Yahoo Finance
7 Outrageous Cards For Those With Excellent Credit
NextAdvisor
Sponsored

China's SenseTime, the world's highest valued AI startup, raises $600M
TechCrunch
This Little-Known 401(k) Trick Can Open the Floodgates to Roth IRA Savings
Motley Fool
SNL roasts Mark Zuckerberg on Weekend Update
TechCrunch
Homeowners Born Before 1985 Get A Big Pay Day
Improve Mortgage
Sponsored

Thursday, March 29, 2018

Letting the Johnson and Johnson LAWSUITS REIN IN, THIS corporation has swindled the worst chemists like dracula stifing the medical industry by producing only DRACONIAN convulsed pagan synthetics that only serve no purpose beneficial. The JNJ organization does not understand how we need to be able to produce pharma drugs that can serve to treat the patient , residuals, and repeat users, whom can have symptoms subside temporarily , however this Junk of A pHAMRMA giants produces secular jeckle and high crimes , that no patient after trying the medication once, wants to be treated again considering the 1st experience with for examples JNJ's On February 7, 2018, the Beasley Allen Law Firm issued a press release stating that “[l]awsuits filed by ovarian cancer and mesothelioma victims are revealing never-before-seen documents from Johnson & Johnson and talc supplier, Imerys, that shed light on just how prevalent asbestos and heavy metals are in the talc used in Baby Powder.” The release stated that “[i]nternal Johnson & Johnson documents from 1972 note that asbestos was found in 100 percent of talc samples tested at the time, but this information was never released publicly.” It further stated that J&J stopped funding a project designed to test talc samples for asbestos contamination once a majority of the sample batches were found to be positive for asbestos.

LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired securities of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ) between February 22, 2013 and February 7, 2018, inclusive (the “Class Period”). JNJ investors have until April 9, 2018 to file a lead plaintiff motion.

To obtain information or actively participate in the class action, please visit the JNJ page on our website at www.glancylaw.com/case/johnson-johnson. Investors that suffered losses on their JNJ investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

The complaint filed in this class action alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) J&J has known for decades that its talc products include asbestos fibers and that the exposure to those fibers can cause ovarian cancer and mesothelioma; and (2) as a result, defendants’ statements about J&J’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On February 5, 2018, CNBC published an article stating that “court proceedings could expose potentially damaging documents” related to J&J’s talc products, such as Johnson’s Baby Powder. On this news, shares of J&J fell $7.29 per share or more than 5%, to close at $130.39 on February 5, 2018.

Then, on February 7, 2018, the Beasley Allen Law Firm issued a press release stating that “[l]awsuits filed by ovarian cancer and mesothelioma victims are revealing never-before-seen documents from Johnson & Johnson and talc supplier, Imerys, that shed light on just how prevalent asbestos and heavy metals are in the talc used in Baby Powder.” The release stated that “[i]nternal Johnson & Johnson documents from 1972 note that asbestos was found in 100 percent of talc samples tested at the time, but this information was never released publicly.” It further stated that J&J stopped funding a project designed to test talc samples for asbestos contamination once a majority of the sample batches were found to be positive for asbestos. On this news, shares of J&J fell $5.06 per share, to close at $126.36 per share on February 8, 2018, thereby further injuring investors.

If you purchased shares of JNJ during the Class Period you may move the Court no later than April 9, 2018 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: he complaint filed in this class action alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) J&J has known for decades that its talc products include asbestos fibers and that the exposure to those fibers can cause ovarian cancer and mesothelioma; and (2) as a result, defendants’ statements about J&J’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased shares of JNJ during the Class Period you may move the Court no later than April 9, 2018 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay and Murray LLP, Los Angeles

Lesley Portnoy, 310-201-9150 or 888-773-9224/

Pages

Convert US Dollar to Bitcoin Calculate